建行北京市分行创新打造科技金融"星火+"党建品牌，全力赋能首都科技成果转化与产业化发展。图为 该行信贷支持的赛诺威盛科技（北京）股份有限公司员工在CT设备生产车间作业。 ...

Core Insights - The rapid adoption of generative AI is transforming investment strategies, shifting focus from semiconductor manufacturers to companies across various sectors that are integrating AI into their operations and products [1] - Generative AI has reached 50% penetration in U.S. households within three years, significantly faster than previous technologies like the postal system and the Internet [1] Investment Landscape - Alger's research categorizes the AI landscape into "Enablers," which include hardware and software providers, and "Adopters," which are companies integrating AI to enhance products and improve productivity [1] - Investment opportunities are emerging not only in infrastructure but also in diverse sectors such as medical devices, financial services, advertising, aerospace, and cybersecurity, all leveraging AI for various applications [1] Sector Applications - Medical device companies are utilizing AI for earlier disease detection, while financial services firms are automating compliance processes to enhance margins [1] - Other sectors are deploying AI for personalized content in advertising, threat detection in aerospace and defense, and automated incident response in cybersecurity [1] - Companies in customer service, logistics, and waste management are also adopting AI to streamline workflows and reduce costs, focusing on internal productivity improvements [1] Investment Fund - The Alger AI Enablers & Adopters ETF (ALAI) invests in both enablers and adopters of AI technology, with a 0.55% expense ratio and launched in April 2024 [1] - Top holdings in the ETF include major technology firms such as Microsoft, Amazon, and Alphabet, alongside semiconductor manufacturers and emerging AI-focused companies [1]

MINNEAPOLIS and BRISBANE, Australia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the full year ended December 31, 2025, and provided a corporate update. 2025 Full Year Highlights & Recent Developments Initiated the global pivotal PARADIGM Tria ...

OrthoPediatrics (NasdaqGM:KIDS) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsCaitlin Cronin - Director of MedTech Equity ResearchDavid Bailey - President and CEOFred Hite - COO and CFOMathew Blackman - Managing Director of Medical Technology Equity ResearchTrip Taylor - Investor RelationsConference Call ParticipantsBenjamin Haynor - Senior Research AnalystMatthew O'Brien - Managing Director and Senior Research AnalystMike Matson - Senior AnalystRavi Misra - VP and Associate Analys ...

DENTSPLY SIRONA (NasdaqGS:XRAY) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker12Good day. Thank you for standing by. Welcome to the Q4 2025 Dentsply Sirona Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your ...

On February 18, 2026, Front Street Capital Management, Inc. reported a buy of 156,069 shares of Enovis (NYSE:ENOV), an estimated $4.61 million trade based on quarterly average pricing. What happened According to a filing with the Securities and Exchange Commission dated February 18, 2026, Front Street Capital Management, Inc. increased its position in Enovis (NYSE:ENOV) by 156,069 shares during the fourth quarter. The estimated transaction value was $4.61 million, calculated using the average unadjusted ...

Ademi LLP Investigates Claims of Securities Fraud against PROCEPT BioRobotics Corporation [Accessibility Statement] Skip NavigationMILWAUKEE, Feb. 26, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against PROCEPT BioRobotics (NASDAQ: PRCT). The investigation results from inaccurate statements PROCEPT BioRobotics may have made regarding its financial statements, business operations and prospects.Click [here] to join our investigation or to obtain additional information, or ...

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Solventum beats quarterly estimates on strong demand for surgical products February 26, 20269:43 PM UTCUpdated ago By Reuters Sign up here. Solventum's MedSurg business, which sells wound dressings and surgical equipment, accounts for more than half the company's revenue. Sales in the segment rose 5.2% from a year earlier to $1.24 billion during the quarter. The company's quarterly revenue cam ...

We improved our quality and manufacturing organizations and established operating mechanisms that are driving disciplined execution. We created a transformation and program management office that is focusing the organization on our most important priorities and driving greater accountability across the company. We also launched a supply chain control tower, providing daily visibility into key operational metrics and performance across our global network. These mechanisms are already translating into improve ...

Record full year 2025 revenue of $236.3 million increased 15% compared to prior yearOperating Cash flow improvement of $22 million in full year 2025Generated $10 million of free cash flow in the fourth quarter, the first quarter of positive free cash flow in Company history WARSAW, Ind., Feb. 26, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial resu ...